Cara Therapeutics' short interest decreases by 5.7%, while some analysts downgrade stock.
Cara Therapeutics (NASDAQ:CARA) has a consensus "Hold" recommendation from six research firms covering the stock, with an average 1-year target price of $3.93. The company has experienced a significant drop in short interest, with short interest decreasing to 2.30 million shares as of May 31st, a 5.7% decrease from May 15th. Some analysts have downgraded the stock, including Stifel Nicolaus, Canaccord Genuity Group, and Needham & Company LLC.
June 20, 2024
3 Articles